Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment.
Unger JM, Till C, Tangen CM, Hershman DL, Goodman PJ, LeBlanc M, Barlow WE, Vaidya R, Minasian LM, Parnes HL, Thompson IM Jr. Unger JM, et al. Among authors: parnes hl. JAMA Oncol. 2024 Nov 7;10(12):1654-62. doi: 10.1001/jamaoncol.2024.4397. Online ahead of print. JAMA Oncol. 2024. PMID: 39509091
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.
Downs TM, Bailey HH, Lozar T, Schmitz NS, Green H, Scarlett CO, Havighurst TC, Twaroski K, DeShong K, Wollmer B, Bivalacqua TJ, Saltzstein DR, Shore N, Kim K, Huang W, Ricke WA, Barroilhet L, House M, Parnes HL, Messing E. Downs TM, et al. Among authors: parnes hl. Cancer Prev Res (Phila). 2025 Jan 6;18(1):31-39. doi: 10.1158/1940-6207.CAPR-24-0194. Cancer Prev Res (Phila). 2025. PMID: 39187984 Clinical Trial.
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. Apolo AB, et al. Among authors: parnes hl. J Clin Oncol. 2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. J Clin Oncol. 2024. PMID: 38954785 Free PMC article. Clinical Trial.
PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
Yilmaz EC, Lin Y, Belue MJ, Harmon SA, Phelps TE, Merriman KM, Hazen LA, Garcia C, Johnson L, Lay NS, Toubaji A, Merino MJ, Patel KR, Parnes HL, Law YM, Wood BJ, Gurram S, Choyke PL, Pinto PA, Turkbey B. Yilmaz EC, et al. Among authors: parnes hl. AJR Am J Roentgenol. 2024 Jan;222(1):e2329964. doi: 10.2214/AJR.23.29964. Epub 2023 Sep 20. AJR Am J Roentgenol. 2024. PMID: 37729551
Screening for Prostate Cancer. Reply.
Pinsky PF, Parnes H. Pinsky PF, et al. Among authors: parnes h. N Engl J Med. 2023 Jul 6;389(1):94. doi: 10.1056/NEJMc2305651. N Engl J Med. 2023. PMID: 37407017 No abstract available.
174 results